Literature DB >> 28360071

Primary care management of overactive bladder symptoms: evaluation and treatment.

Sarah Itam1, Gurpreet Singh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28360071      PMCID： PMC5565819          DOI： 10.3399/bjgp17X690413

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  5 in total

1.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

2.  EAU guidelines on urinary incontinence.

Authors:  Joachim W Thüroff; Paul Abrams; Karl-Erik Andersson; Walter Artibani; Christopher R Chapple; Marcus J Drake; Christian Hampel; Andreas Neisius; Annette Schröder; Andrea Tubaro
Journal:  Eur Urol       Date:  2010-11-24       Impact factor: 20.096

3.  Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

Authors:  Marcus J Drake; Christopher Chapple; Ahmet A Esen; Stavros Athanasiou; Javier Cambronero; David Mitcheson; Sender Herschorn; Tahir Saleem; Moses Huang; Emad Siddiqui; Matthias Stölzel; Claire Herholdt; Scott MacDiarmid
Journal:  Eur Urol       Date:  2016-03-08       Impact factor: 20.096

Review 4.  Comorbidities associated with overactive bladder.

Authors:  J S Brown; W F McGhan; S Chokroverty
Journal:  Am J Manag Care       Date:  2000-07       Impact factor: 2.229

Review 5.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.

Authors:  Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer
Journal:  Int Urogynecol J       Date:  2009-11-25       Impact factor: 2.894
  5 in total
  1 in total

1.  High risk of lower urinary tract symptoms in patients with irritable bowel syndrome.

Authors:  F Zingone; P Iovino; A Santonicola; S Gallotta; C Ciacci
Journal:  Tech Coloproctol       Date:  2017-06-24       Impact factor: 3.781
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.